Observational studyLung2026
Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry.
Observational study in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915511 (Idiopathic Pulmonary Fibrosis Prospective Outcomes), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePulmonary fibrosis may impair an individual's ability to work. We assessed the extent, cost and factors associated with workplace productivity loss among patients with progressive pulmonary fibrosis (PPF).
methodsThe multi-center ILD-PRO Registry enrolled US patients with progressive interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis. Workplace productivity loss was assessed using the Work Productivity and Activity Impairment (WPAI) questionnaire. Associations between patient characteristics and workplace productivity loss among employed patients were analyzed using logistic regression.
resultsAmong 175 employed patients of 597 who completed the WPAI questionnaire, 58.3% were female, median age was 58 years, median forced vital capacity (FVC) was 58.7% predicted; 20.0% used oxygen with activity and at rest. In the past 7 days, mean (SD) hours worked was 32.9 (15.8) and mean (SD) working hours lost was 10 (12). Mean (SD) percentage of working hours lost was 24.4 (30.2). Mean (SD) working hours lost due to absenteeism and presenteeism were 4 (9) and 8 (11), respectively. Among patients with any productivity loss, the estimated mean (SD) annual cost of productivity loss was $24,815 ($17,917). Lower FVC % predicted, higher (worse) St. George's Respiratory Questionnaire scores and lower (worse) Cough and Sputum Assessment Questionnaire cough impact and symptoms scores were associated with greater odds of productivity loss.
conclusionsPatients with PPF showed significant impairment in workplace productivity. Worse lung function and worse scores on patient-reported outcomes were associated with a greater likelihood of productivity loss. Trial Registration ClinicalTrials.gov; No: NCT01915511; registered August 5, 2013; URL: www. CLINICALTRIALS: gov .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.